Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is a fatal neurodegenerative disease characterized by abnormal motor coordination, cognitive decline and psychiatric disorders. This disease is caused by an expanded CAG trinucleotide repeat in the gene encoding the protein huntingtin. Reduced levels of brain-derived neurotrophic factor (BDNF) in the brain, which results from transcriptional inhibition and axonal transport deficits mediated by mutant huntingtin, have been suggested as critical factors underlying selective neurodegeneration in both HD patients and HD mouse models. BDNF activates its high-affinity receptor TrkB and promotes neuronal survival; restoring BDNF signaling is thus of particular therapeutic interest. In the present study, we evaluated the ability of a small-molecule TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) and its synthetic derivative 4'-dimethylamino-7,8- dihydroxyflavone (4'-DMA-7,8-DHF) to protect neurons in the well-characterized N171-82Q HD mouse model. We found that chronic administration of 7, 8-DHF (5 mg/kg) or 4'-DMA-7,8-DHF (1 mg/kg) significantly improved motor deficits, ameliorated brain atrophy and extended survival in these N171-82Q HD mice. Moreover, 4'-DMA-7,8-DHF preserved DARPP32 levels in the striatum and rescued mutant huntingtin-induced impairment of neurogenesis in the N171-82Q HD mice. These data highlight consideration of TrkB as a therapeutic target in HD and suggest that small-molecule TrkB agonists that penetrate the brain have high potential to be further tested in clinical trials of HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p75 and Trk: A two-receptor system
Chao, M. V., & Hempstead, B. L. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93922-k · Cited by 857 · cited 1×
“Mature BDNF acts via two receptors, the TrkB tyrosine kinase receptor and p75 neurotrophin receptor (p75NTR) (17).”
BackgroundTrkB Regulates Hippocampal Neurogenesis and Governs Sensitivity to Antidepressive Treatment
Li, Y., Luikart, B. W., Birnbaum, S., Chen, J., Kwon, C.-H., Kernie, S. G., Bassel-Duby, R., & Parada, L. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.023 · Cited by 634
Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · cited 1×
“Male mice were used in our studies because we found gender-dependent phenotypic differences in N171-82Q HD mice (13).”
MethodSelf-citationSmall molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406 · cited 1×
“For example, small-molecule BDNF mimetics identified by in silico screening with a BDNF loopdomain pharmacophore, followed by low-throughput in vitro screening in mouse fetal hippocampal neurons, have been shown to prevent neuronal degeneration in rodents (52) and improved respiratory function in a mouse model of Rett…”
BackgroundDevi, L., & Ohno, M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.191 · Cited by 282 · cited 1×
“Since the discovery of the brain-penetrable TrkB agonist 7,8-DHF, multiple studies have described the beneficial effects of 7,8-DHF in a variety of models of neurological disorders, including Alzheimer’s disease (19), Parkinson’s disease (18), stroke (23), Rett Syndrome (21), depression and stress or aging-related cog…”
BackgroundBDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice
Xie, Y., Hayden, M. R., & Xu, B. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1637-10.2010 · Cited by 236
Zuccato, C., Marullo, M., Conforti, P., MacDonald, M. E., Tartari, M., & Cattaneo, E. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00111.x · Cited by 231
Liu, X., Chan, C.-B., Jang, S.-W., Pradoldej, S., Huang, J., He, K., Phun, L. H., France, S., Xiao, G., Jia, Y., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101206p · Cited by 208 · cited 3×
“Previous studies reported that 4′-DMA-7,8-DHF increased neurogenesis in normal mice (19).”
BackgroundResultSelf-citationCognitive disorders and neurogenesis deficits in Huntington’s disease mice are rescued by fluoxetine
Grote, H. E., Bull, N. D., Howard, M. L., Van Dellen, A., Blakemore, C., Bartlett, P. F., & Hannan, A. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04365.x · Cited by 179
Schmid, D. A., Yang, T., Ogier, M., Adams, I., Mirakhur, Y., Wang, Q., Massa, S. M., Longo, F. M., & Katz, D. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0865-11.2012 · Cited by 152
Liu, X., Chan, C.-B., Qi, Q., Xiao, G., Luo, H. R., He, X., & Ye, K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301099x · Cited by 60 · cited 1×
“, Pharmacology In press) and 4′-DMA-7,8-DHF (51).”
Self-citation
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Self-citationHuntington’s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies
Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 507
Liu, C., Chan, C. B., & Ye, K. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-015-0048-7 · Cited by 195
“There is mounting evidence that 7,8-DHF mimics the physiological activities of BDNF and exhibits promising therapeutic efficacy toward various neurological diseases including Parkinson’s disease (PD) [26], Huntington’s disease (HD) [27], ALS (Amyotrophic lateral sclerosis) [53, 54], Alzheimer’s disease (AD) [55–58], P…”
BackgroundSelf-citationGeisler, J. G. (2019) · Cells · doi:10.3390/cells8030280 · Cited by 104
Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists
Boltaev, U., Meyer, Y., Tolibzoda, F., Jacques, T., Gassaway, M., Xu, Q., Wagner, F., Zhang, Y.-L., Palmer, M., Holson, E., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aal1670 · Cited by 94
“For example, systemic administration of 7,8-DHF to mice has been shown to have antidepressant effects (52), prevent memory loss in an Alzheimer’s disease model (53), and improve motor function in Huntington’s disease models (54).”
Background
Metadata
- Authors
- Jiang, M., Peng, Q., Liu, X., Jin, J., Hou, Z., Zhang, J., Mori, S., Ross, C. A., Ye, K., & Duan, W.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-27
- Volume
- 22
- Issue
- 12
- Pages
- 2462-2470
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2102274021
- Cited by
- 129
- References
- 11
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.